What is Palbociclib?

What is Palbociclib?

Palbociclib is an oral anticancer drug whose active ingredient is palbociclib. It is a targeted therapy specifically used to treat certain types of advanced breast cancer. It is not typically used as a monotherapy, but rather in combination with hormone therapies such as aromatase inhibitors or fulvestrant. Palbociclib is supplied as film-coated tablets in three strengths: 75 mg, 100 mg, and 125 mg, allowing physicians to adjust the dosage based on the patient's condition.

How does Palbociclib exert its anticancer effect?

p>    Palbociclib's mechanism of action involves selectively inhibiting two key proteins inside cells: cyclin-dependent kinases 4 and 6. These kinases play a central regulatory role in the growth and division of both normal and cancer cells. When palbociclib blocks the activity of these kinases, the cell cycle of cancer cells is arrested, preventing them from continuing to proliferate rapidly. This inhibition significantly slows tumor growth and delays overall disease progression. Because the growth of many breast cancer cells depends on these kinases, palbociclib is particularly effective against breast cancer that is hormone receptor-positive and human epidermal growth factor receptor 2-negative.

Which patients are suitable for Palbociclib?

Palbociclib is used to treat patients with advanced breast cancer that has locally spread or metastasized to distant sites, specifically when the tumor type is hormone receptor-positive and human epidermal growth factor receptor 2-negative. This means the tumor cells' growth is stimulated by hormones but they do not overexpress the HER2 protein. For these patients, combining palbociclib with endocrine therapy (such as letrozole, anastrozole, or fulvestrant) can more effectively control the disease. It is important to note that this drug is not indicated for children or adolescents under 18 years of age, as its safety and efficacy have not been established in this population.